Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan

Shumpei Yokota, Ryuta Nishikomori, Hidetoshi Takada, Masako Kikuchi, Tomo Nozawa, Taichi Kanetaka, Toshitaka Kizawa, Takako Miyamae, Masaaki Mori, Toshio Heike, Toshiro Hara, Tomoyuki Imagawa

Research output: Contribution to journalReview article

Abstract

Cryopyrin-associated periodic syndrome (CAPS) is an orphan disease with incidence of about one in 1,000,000 persons. This autoinflammatory disease develops in the neonatal period or early childhood, with various inflammatory symptoms occurring repeatedly throughout the patient's lifetime. It is caused by abnormality of the NLRP3 protein which mediates the intracellular signal transduction mechanism of inflammatory processes, resulting in continuous overproduction of interleukin (IL)-1β, which induces chronic inflammation and progressive tissue damage. Definitive diagnosis of CAPS is difficult, and treatment has also been difficult because of a lack of effective medications in Japan. Clinical studies of human anti-human IL-1β monoclonal antibody (canakinumab) treatment were conducted in Japan, and approval was granted for therapeutic use of canakinumab for CAPS in September 2011. Similar to other biological drugs, canakinumab is clinically highly effective. However, sufficient attention to the method of use and adverse drug reactions is necessary. This guidance describes the use of canakinumab in Japan for CAPS in relation to exclusion criteria, method of use, evaluation criteria, and adverse drug reactions.

Original languageEnglish
Pages (from-to)425-429
Number of pages5
JournalModern Rheumatology
Volume23
Issue number3
DOIs
Publication statusPublished - May 1 2013

Fingerprint

Cryopyrin-Associated Periodic Syndromes
Japan
Drug-Related Side Effects and Adverse Reactions
Interleukin-1
Therapeutic Uses
Rare Diseases
Signal Transduction
Monoclonal Antibodies
Inflammation
canakinumab
Incidence
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Rheumatology

Cite this

Yokota, S., Nishikomori, R., Takada, H., Kikuchi, M., Nozawa, T., Kanetaka, T., ... Imagawa, T. (2013). Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan. Modern Rheumatology, 23(3), 425-429. https://doi.org/10.1007/s10165-012-0769-8

Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan. / Yokota, Shumpei; Nishikomori, Ryuta; Takada, Hidetoshi; Kikuchi, Masako; Nozawa, Tomo; Kanetaka, Taichi; Kizawa, Toshitaka; Miyamae, Takako; Mori, Masaaki; Heike, Toshio; Hara, Toshiro; Imagawa, Tomoyuki.

In: Modern Rheumatology, Vol. 23, No. 3, 01.05.2013, p. 425-429.

Research output: Contribution to journalReview article

Yokota, S, Nishikomori, R, Takada, H, Kikuchi, M, Nozawa, T, Kanetaka, T, Kizawa, T, Miyamae, T, Mori, M, Heike, T, Hara, T & Imagawa, T 2013, 'Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan', Modern Rheumatology, vol. 23, no. 3, pp. 425-429. https://doi.org/10.1007/s10165-012-0769-8
Yokota, Shumpei ; Nishikomori, Ryuta ; Takada, Hidetoshi ; Kikuchi, Masako ; Nozawa, Tomo ; Kanetaka, Taichi ; Kizawa, Toshitaka ; Miyamae, Takako ; Mori, Masaaki ; Heike, Toshio ; Hara, Toshiro ; Imagawa, Tomoyuki. / Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan. In: Modern Rheumatology. 2013 ; Vol. 23, No. 3. pp. 425-429.
@article{5542929f38a64f4bb750a814883f28a4,
title = "Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan",
abstract = "Cryopyrin-associated periodic syndrome (CAPS) is an orphan disease with incidence of about one in 1,000,000 persons. This autoinflammatory disease develops in the neonatal period or early childhood, with various inflammatory symptoms occurring repeatedly throughout the patient's lifetime. It is caused by abnormality of the NLRP3 protein which mediates the intracellular signal transduction mechanism of inflammatory processes, resulting in continuous overproduction of interleukin (IL)-1β, which induces chronic inflammation and progressive tissue damage. Definitive diagnosis of CAPS is difficult, and treatment has also been difficult because of a lack of effective medications in Japan. Clinical studies of human anti-human IL-1β monoclonal antibody (canakinumab) treatment were conducted in Japan, and approval was granted for therapeutic use of canakinumab for CAPS in September 2011. Similar to other biological drugs, canakinumab is clinically highly effective. However, sufficient attention to the method of use and adverse drug reactions is necessary. This guidance describes the use of canakinumab in Japan for CAPS in relation to exclusion criteria, method of use, evaluation criteria, and adverse drug reactions.",
author = "Shumpei Yokota and Ryuta Nishikomori and Hidetoshi Takada and Masako Kikuchi and Tomo Nozawa and Taichi Kanetaka and Toshitaka Kizawa and Takako Miyamae and Masaaki Mori and Toshio Heike and Toshiro Hara and Tomoyuki Imagawa",
year = "2013",
month = "5",
day = "1",
doi = "10.1007/s10165-012-0769-8",
language = "English",
volume = "23",
pages = "425--429",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan

AU - Yokota, Shumpei

AU - Nishikomori, Ryuta

AU - Takada, Hidetoshi

AU - Kikuchi, Masako

AU - Nozawa, Tomo

AU - Kanetaka, Taichi

AU - Kizawa, Toshitaka

AU - Miyamae, Takako

AU - Mori, Masaaki

AU - Heike, Toshio

AU - Hara, Toshiro

AU - Imagawa, Tomoyuki

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Cryopyrin-associated periodic syndrome (CAPS) is an orphan disease with incidence of about one in 1,000,000 persons. This autoinflammatory disease develops in the neonatal period or early childhood, with various inflammatory symptoms occurring repeatedly throughout the patient's lifetime. It is caused by abnormality of the NLRP3 protein which mediates the intracellular signal transduction mechanism of inflammatory processes, resulting in continuous overproduction of interleukin (IL)-1β, which induces chronic inflammation and progressive tissue damage. Definitive diagnosis of CAPS is difficult, and treatment has also been difficult because of a lack of effective medications in Japan. Clinical studies of human anti-human IL-1β monoclonal antibody (canakinumab) treatment were conducted in Japan, and approval was granted for therapeutic use of canakinumab for CAPS in September 2011. Similar to other biological drugs, canakinumab is clinically highly effective. However, sufficient attention to the method of use and adverse drug reactions is necessary. This guidance describes the use of canakinumab in Japan for CAPS in relation to exclusion criteria, method of use, evaluation criteria, and adverse drug reactions.

AB - Cryopyrin-associated periodic syndrome (CAPS) is an orphan disease with incidence of about one in 1,000,000 persons. This autoinflammatory disease develops in the neonatal period or early childhood, with various inflammatory symptoms occurring repeatedly throughout the patient's lifetime. It is caused by abnormality of the NLRP3 protein which mediates the intracellular signal transduction mechanism of inflammatory processes, resulting in continuous overproduction of interleukin (IL)-1β, which induces chronic inflammation and progressive tissue damage. Definitive diagnosis of CAPS is difficult, and treatment has also been difficult because of a lack of effective medications in Japan. Clinical studies of human anti-human IL-1β monoclonal antibody (canakinumab) treatment were conducted in Japan, and approval was granted for therapeutic use of canakinumab for CAPS in September 2011. Similar to other biological drugs, canakinumab is clinically highly effective. However, sufficient attention to the method of use and adverse drug reactions is necessary. This guidance describes the use of canakinumab in Japan for CAPS in relation to exclusion criteria, method of use, evaluation criteria, and adverse drug reactions.

UR - http://www.scopus.com/inward/record.url?scp=84877757977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877757977&partnerID=8YFLogxK

U2 - 10.1007/s10165-012-0769-8

DO - 10.1007/s10165-012-0769-8

M3 - Review article

VL - 23

SP - 425

EP - 429

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 3

ER -